Europe
Clinical News
Informatics
Industry News
Practice Management
Education
Subspecialties
More
Sign In
Breast Imaging
CV
Chest
Emergency
GI
GU
Head & Neck
Interventional
Physics
MSK
Neuro
Nuclear
Pediatric
Radiation Oncology
Genitourinary Radiology: Page 53
CEUS helps detect renal cell carcinoma
By
Erik L. Ridley
Sunday, November 27 | 11:55 a.m.-12:05 p.m. | SSA10-08 | Room E353BContrast-enhanced ultrasound (CEUS) can differentiate between benign and malignant renal masses, according to this study from a Canadian research team.
November 13, 2011
CEUS perfusion imaging boosts prostate cancer detection
By
Erik L. Ridley
Sunday, November 27 | 11:35 a.m.-11:45 a.m. | SSA21-06 | Room S504ABA contrast-enhanced ultrasound (CEUS) perfusion imaging technique could improve lesion detection in prostate peripheral zone tissue, according to a research initiative led by a contrast developer.
November 13, 2011
Choline-PET/CT in recurrent prostate cancer cases could alter therapy
By
Wayne Forrest
Tuesday, November 29 | 11:50 a.m.-12:00 p.m. | SSG12-09 | Room S505ABCholine-PET/CT can greatly affect therapy management for recurrent prostate cancer patients and should be considered for restaging, according to a new study by Swiss researchers.
November 7, 2011
Novel molecular imaging technique could help prostate cancer patients
By
Wayne Forrest
Monday, November 28 | 11:20 a.m.-11:30 a.m. | SSC09-06 | Room S504CDIn this paper presentation, Dutch researchers will show early promising results for two novel molecular imaging techniques to detect and manage lymph node metastases in prostate cancer patients.
November 7, 2011
IsoRay receives MD Anderson order
By
AuntMinnie.com staff writers
Medical isotope developer IsoRay Medical said that MD Anderson Cancer Center at the University of Texas has begun ordering its cesium-131 brachytherapy seeds.
October 9, 2011
Varian touts prostate cancer study at ASTRO
By
AuntMinnie.com staff writers
Radiation therapy developer Varian Medical Systems is highlighting early results from a prospective phase II trial showing that patients with low-risk prostate cancer who underwent stereotactic body radiation therapy experienced minimal toxicities.
October 4, 2011
ASTRO: IMRT produces less rectal toxicity in prostate cancer
By
Cynthia E. Keen
Intensity-modulated radiation therapy (IMRT) causes fewer bowel and rectal toxicities than 3D conformal radiation therapy, according to study findings to be presented October 3 at the plenary session of the American Society for Radiation Oncology (ASTRO) annual meeting.
September 27, 2011
Hypofractionated RT works for prostate cancer
By
AuntMinnie.com staff writers
A hypofractionated course of radiation therapy is as effective as conventional radiation therapy in reducing intermediate- to high-risk prostate cancer recurrence, according to five-year outcome results of a clinical trial to be presented at next week's American Society for Radiation Oncology annual meeting.
September 26, 2011
Early MRI before surgery predicts rectal cancer survival
By
Wayne Forrest
An MRI scan after initial chemotherapy and before surgery may predict long-term outcome for patients with advanced rectal cancer and identify individuals who could benefit from more aggressive therapy prior to surgery, according to a study published online August 29 in the
Journal of Clinical Oncology
.
August 30, 2011
Calypso co-sponsors prostate cancer fundraiser
By
AuntMinnie.com staff writers
Electromagnetic localization technology developer Calypso Medical Technologies is partnering with Zero, a nonprofit Washington, DC-based organization to end prostate cancer, to co-sponsor a series of fundraising 5K and 10K races in five cities.
August 16, 2011
Researchers study Calypso technology
By
AuntMinnie.com staff writers
A new study has been launched to analyze hypofractionated stereotactic body radiation therapy using Calypso Medical Technologies' GPS for the Body technology for real-time tracking of cancerous tumors during prostate radiation therapy.
August 1, 2011
RT + ADT increases survival of prostate cancer patients
By
Cynthia E. Keen
Adding short-term androgen-deprivation therapy (ADT) to radiation therapy (RT) for early-stage prostate cancer improves long-term survival for men at intermediate risk, according to trial results from the Radiation Therapy Oncology Group published in the July 14
New England Journal of Medicine
.
July 17, 2011
Previous Page
Page 53 of 93
Next Page